4.3 Article

High CD6 and low chemokine receptor expression on peripheral blood lymphocytes correlates with MRI gadolinium enhancement in MS

期刊

JOURNAL OF NEUROIMMUNOLOGY
卷 276, 期 1-2, 页码 187-194

出版社

ELSEVIER
DOI: 10.1016/j.jneuroim.2014.08.620

关键词

Multiple sclerosis (MS); CD6; Peripheral mononuclear cells (PBMC); MRI; Gadolinium enhancing lesion; Chemokine receptors

向作者/读者索取更多资源

Correlation between gadolinium-enhancing [Gd(+)] lesions on MRI and expression of CD6 molecules and a group of chemokine receptors on peripheral blood (PB) and cerebrospinal fluid (CSF) immune cells was measured in multiple sclerosis (MS) patients. Twenty remitting-relapsing MS patients with (n = 10) and without (n = 10) Gd(+) lesions entered the study. mRNA and surface expression of CD6 and CCR1, CCR2, CCR3 and CCR5 was measured by immunostaining and flow cytometry. Expression of mRNA and surface staining for CD6 in PB T lymphocytes was increased in Gd(+) compared to Gd(-) patients (p < 0.01; p < 0.05, respectively). CD6 mRNA correlated with the number and size of Gd(+) lesions (r = 0.67, and r = 0.65 respectively). mRNA and surface expression for CCR1, CCR2, and CCR3 in PB cells was lower in Gd(+) compared to Gd(-) MS patients (p < 0.05, p < 0.05). The frequency of cells co-expressing CD6 with CCR1 and CCR5 was low in PB T lymphocytes and high in CSF (p < 0.05, p < 0.05). These results suggest that Gd(+) correlates with increased expression of CD6 and decreased expression of chemokine receptors on PB T lymphocytes. Co-expression of CD6 with CCR1 and CCR5 predisposes cells for transmigration into CSF. 2014 Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis

Agnieszka Machlanska, Grzegorz Helbig, Karolina Chromik, Magdalena Zapala, Bartosz Zwiernik, Krzysztof Selmaj

Summary: This case study describes a patient with multiple sclerosis (MS) who developed hemophagocytic lymphohistiocytosis (HLH) while being treated with ocrelizumab. The patient met six out of eight HLH diagnostic criteria, including fever, splenomegaly, cytopenia, hypertriglyceridemia, hypofibrinogenemia, elevated serum ferritin levels, and low natural killer (NK) cells. HLH should be considered in MS patients showing fever and malaise following ocrelizumab treatment.

MULTIPLE SCLEROSIS JOURNAL (2021)

Article Clinical Neurology

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program

Krzysztof W. Selmaj, Jeffrey A. Cohen, Giancarlo Comi, Amit Bar-Or, Douglas L. Arnold, Lawrence Steinman, Hans Peter Hartung, Xavier Montalban, Eva Kubala Havrdova, Bruce A. C. Cree, Neil Minton, James K. Sheffield, Ning Ding, Ludwig Kappos

Summary: This study conducted an integrated safety analysis of extended exposure to ozanimod in RMS participants, showing no new safety concerns in patients with long-term exposure to the drug and consistent results with phase 3 trials.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Article Clinical Neurology

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Hans-Peter Hartung, Tobias Derfuss, Bruce A. C. Cree, Maria Pia Sormani, Krzysztof Selmaj, Jonathan Stutters, Ferran Prados, David MacManus, Hans-Martin Schneble, Estelle Lambert, Herve Porchet, Robert Glanzman, David Warne, Francois Curtin, Gabrielle Kornmann, Benedicte Buffet, David Kremer, Patrick Kury, David Leppert, Thomas Ruckle, Frederik Barkhof

Summary: The study did not meet its primary endpoint, but at 48 weeks participants treated with 18 mg/kg temelimab had fewer new T1-hypointense lesions. They also showed consistent, although statistically non-significant, reductions in brain atrophy and magnetization transfer ratio decrease compared to the placebo/comparator group. These trends were sustained over 96 weeks with no safety issues emerging.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Biochemistry & Molecular Biology

Effect of Multiple Sclerosis Cerebrospinal Fluid and Oligodendroglia Cell Line Environment on Human Wharton's Jelly Mesenchymal Stem Cells Secretome

Karolina Salwierak-Glosna, Pawel Piatek, Malgorzata Domowicz, Mariola Swiderek-Matysiak

Summary: Multiple sclerosis (MS) is an autoimmune neurological disorder. Experimental therapies using mesenchymal stem cells (MSCs) have shown promising immunomodulatory potential. In this study, we investigated the effect of cerebrospinal fluid (CSF) obtained from MS patients on the secretory activity of Wharton's jelly-derived MSCs (WJ-MSCs), and further explored the interactions between WJ-MSCs and human oligodendroglia cell line (OLs). Our results demonstrate the diverse immunomodulatory properties of WJ-MSCs and how these effects can be influenced by the transplantation milieu.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Clinical Neurology

Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis

Bruno Brochet, Raymond Hupperts, Dawn Langdon, Alessandra Solari, Fredrik Piehl, Jeannette Lechner-Scott, Xavier Montalban, Krzysztof Selmaj, Martin Valis, Konrad Rejdak, Eva K. Havrdova, Francesco Patti, Nektaria Alexandri, Axel Nolting, Birgit Keller

Summary: This study aims to evaluate the effect of cladribine tablets on HRQoL in highly active multiple sclerosis patients. The study design is a two-year, pre-planned interim analysis focusing on treatment satisfaction, safety, and tolerability. The results showed high treatment satisfaction and good tolerability of cladribine tablets in highly active multiple sclerosis patients.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Review Clinical Neurology

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, Maria Pia Amato, Tobias Derfuss, Franziska Di Pauli, Ellen Iacobaeus, Marcin Mycko, Hesham Abboud, Anat Achiron, Angelo Bellinvia, Alexey Boyko, Jean-Laurent Casanova, David Clifford, Ruth Dobson, Mauricio F. Farez, Massimo Filippi, Kathryn C. Fitzgerald, Mattia Fonderico, Riadh Gouider, Yael Hacohen, Kerstin Hellwig, Bernhard Hemmer, Ludwig Kappos, Filipa Ladeira, Christine Lebrun-Frenay, Celine Louapre, Melinda Magyari, Matthias Mehling, Celia Oreja-Guevara, Lekha Pandit, Caroline Papeix, Fredrik Piehl, Emilio Portaccio, Isabel Ruiz-Camps, Krzysztof Selmaj, Steve Simpson-Yap, Aksel Siva, Per Soelberg Sorensen, Maria Pia Sormani, Maria Trojano, Adi Vaknin-Dembinsky, Sandra Vukusic, Brian Weinshenker, Heinz Wiendl, Alexander Winkelmann, Maria Isabel Zuluaga Rodas, Mar Tintore, Bruno Stankoff

Summary: In recent years, there have been rapid developments in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), with a wide range of disease-modifying treatments (DMTs) now available. However, most DMTs come with the risk of adverse events, particularly infections. To address this, an international workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held in April 2021 to review the current knowledge on infection risks associated with DMT use in MS and NMOSD patients, and to discuss strategies for risk mitigation. The workshop also explored specific populations, such as children, pregnant women, individuals with comorbidities, and those living in regions with high infection burden, as well as the impact of the ongoing SARS-CoV-2 pandemic on DMT-associated infectious risks.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Immunology

Impact of Diminished Expression of circRNA on Multiple Sclerosis Pathomechanisms

Marcin P. Mycko, Anna E. Zurawska, Igor Selmaj, Krzysztof W. Selmaj

Summary: Circular RNA plays a crucial role in regulating the expression and function of microRNA and post-transcriptional regulation. Recent research suggests its involvement in the pathomechanism of multiple sclerosis, particularly in oxidative stress, blood-brain barrier permeability, microglia function, and extracellular matrix molecules altering the microenvironment and inhibiting oligodendrocyte progenitor cells.

FRONTIERS IN IMMUNOLOGY (2022)

Review Clinical Neurology

Fluid phase biomarkers in multiple sclerosis

Krzysztof W. Selmaj, Marcin P. Mycko, Roberto Furlan, Konrad Rejdak

Summary: Multiple sclerosis is a highly heterogeneous disorder, and finding reliable biomarkers is crucial. Recent research suggests that cerebrospinal fluid and serum levels of neurofilament light chains could be promising biomarkers for MS. Additionally, extracellular RNA and extracellular vesicles may also be potential biomarkers. This new approach holds promise for MS diagnosis and prognosis.

CURRENT OPINION IN NEUROLOGY (2022)

Article Clinical Neurology

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Bruce A. C. Cree, Krzysztof W. Selmaj, Lawrence Steinman, Giancarlo Comi, Amit Bar-Or, Douglas L. Arnold, Hans-Peter Hartung, Xavier Montalban, Eva K. Havrdova, James K. Sheffield, Neil Minton, Chun-Yen Cheng, Diego Silva, Ludwig Kappos, Jeffrey A. Cohen

Summary: This study characterizes the long-term safety and efficacy of ozanimod in the treatment of relapsing forms of multiple sclerosis. The findings confirm a favorable safety profile and sustained benefit in clinical outcomes and magnetic resonance imaging measures of disease activity.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations

Wallace J. Brownlee, Christian Wolf, Hans-Peter Hartung, Theo Dingermann, Nadia Anshasi, Richard A. C. Clark, Maria Trojano, Krzysztof Selmaj, Bernard M. J. Uitdehaag, Carmen Tur, Jens Wuerfel, Gabriele Dallmann, Julian Witte, Martina Sintzel, Olga Bobrovnikova, Jeffrey A. Cohen

Summary: This study identified best practices for the development and use of follow-on disease-modifying treatments (FO-DMTs) through the appraisal of published evidence. The consensus reached by a multidisciplinary panel supports the safe and effective use of FO-DMTs in treating multiple sclerosis. The findings may contribute to enhanced quality standards for FO-DMTs use in other regions.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Medicine, General & Internal

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

Lawrence Steinman, Edward Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, DeRen Huang, Krzysztof Selmaj, Daniel Wynn, Gary Cutter, Koby Mok, Yanzhi Hsu, Yihuan Xu, Michael S. Weiss, Jenna A. Bosco, Sean A. Power, Lily Lee, Hari P. Miskin, Bruce A. C. Cree

Summary: Ublituximab shows promise as a treatment for relapsing multiple sclerosis, reducing relapse rates and brain lesions compared to teriflunomide over a 96-week period. However, it does not significantly decrease the risk of disability worsening.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Clinical Neurology

Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis

Monika Grudziecka Pyrek, Krzysztof Selmaj

Summary: This study assessed axonal and neuronal damage in the retina of patients with familial and sporadic multiple sclerosis. The results showed that there was no significant difference in retinal thickness and macular volume between the two forms of multiple sclerosis, but both forms had a significant reduction compared to healthy controls. This suggests that retinal damage may be a common feature of multiple sclerosis.

FRONTIERS IN NEUROLOGY (2022)

Article Clinical Neurology

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis The Antelope Phase 3 Randomized Clinical Trial

Bernhard Hemmer, Heinz Wiendl, Karsten Roth, Hendrik Wessels, Josef Hoefler, Cyrill Hornuss, Bernd Liedert, Krzysztof Selmaj

Summary: This study aimed to evaluate the matching efficacy, safety, and immunogenicity between biosim-NTZ and ref-NTZ in patients with RRMS. The results showed that biosim-NTZ matched ref-NTZ in terms of efficacy, safety, and immunogenicity. This study supports the use of biosim-NTZ as a biosimilar alternative for treating RRMS.

JAMA NEUROLOGY (2023)

Article Clinical Neurology

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Colin M. Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F. Hunter, Krzysztof W. Selmaj, Hans-Peter Hartung, Eva K. Havrdova, Christopher C. LaGanke, Tjalf Ziemssen, Bart Van Wijmeersch, Sven G. Meuth, David H. Margolin, Elizabeth M. Poole, Darren P. Baker, Peter A. Senior

Summary: This study aimed to describe the endocrine and multiple sclerosis outcomes over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients. The results showed that the common adverse event of this treatment was autoimmune thyroid events, but it did not affect the disease course.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2023)

Article Clinical Neurology

Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study

Peter Rieckmann, Robert Zivadinov, Alexey Boyko, Krzysztof Selmaj, Jessica K. Alexander, Shaul Kadosh, Svetlana Rubinchick, Emily Bernstein-Hanlon, Yafit Stark, Natalia Ashtamker, Mat D. Davis, Omar Khan

Summary: The study showed that GA40 treatment provided clinical benefit for up to seven years in patients with relapsing multiple sclerosis, resulting in sustained efficacy and good tolerability.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2021)

暂无数据